Short-term Results of MRgFUS for Patients with Adenomyosis: Symptomatic Relief and Paid Reduction

The objective of this study was to evaluate the degree of symptomatic relief obtained after treatment with MRgFUS in patients with adenomyosis. Quality of life and pain assessment questionnaires were collected from 35 women, on the day of treatment and up to 6 months after treatment, indicated that the treatment was safe and there was a significant reduction in symptoms.